CASI Pharmaceuticals (CASI) Price & Analysis

Compare

470 Followers

CASI Stock Chart & Stats

$0.93

-$0.35(-10.90%)

At close: Jan 08 4:00 PM EST

$0.93

-$0.35(-10.90%)

Day’s Range― - ―

52-Week Range$0.93 - $4.05

Previous CloseN/A

Volume17.83K

Average Volume (3M)219.83K

Market Cap

$20.61M

Enterprise Value$30.27M

Total Cash (Recent Filing)$4.68M

Total Debt (Recent Filing)$18.86M

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Apr 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding15,492,681

10 Day Avg. Volume60,876

30 Day Avg. Volume219,829

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)23.45

Price to Sales (P/S)1.52

P/FCF Ratio-1.47

Enterprise Value/Market Cap1.47

Enterprise Value/Revenue1.13

Enterprise Value/Gross Profit3.15

Enterprise Value/Ebitda-0.73

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt ReductionThe sale of the China business to Kaixin allows the company to eliminate $20M of existing debt, improving its financial position.

Product DevelopmentCID-103 has shown superior activity and reduced toxicity compared to existing CD38 inhibitors in preclinical and Phase 1 studies, indicating strong potential for successful development.

Strategic ManagementThe appointment of David Cory as the company’s new CEO, who has more than 30 years of experience in the biotech and pharma sectors, is seen as beneficial for the company’s new direction.

Bears Say

Financial PerformanceCASI reported revenues of $4.2M and a net loss of $0.86 per share for the quarter, which was below the consensus estimated revenue of $6.3M and net loss of $0.47 per share.

Licensing And RevenueThe company received a Termination Process Letter to withdraw the Evomela license following a wind-down period, which impacts the company's Chinese business revenues.

Revenue ImpactThe company reported lower-than-expected revenues, which fell 16% year-over-year, primarily due to increased generic competition for Evomela in China.

CASI Pharmaceuticals News

Casi Pharmaceuticals appoints James Huang as non-executive chairman

CASI Pharmaceuticals (CASI) announced that its Board of Directors unanimously voted to appoint James Huang, a current independent...

15d ago

CASI

CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman

CASI Pharmaceuticals ( ($CASI) ) has shared an update. On November 19, 2025, CASI Pharmaceuticals announced a significant...

15d ago

CASI

CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal

An update from CASI Pharmaceuticals ( ($CASI) ) is now available. On November 14, 2025, CASI Pharmaceuticals announced...

19d ago

CASI

CASI Pharmaceuticals Appeals Nasdaq Delisting Determination

An announcement from CASI Pharmaceuticals ( ($CASI) ) is now available. CASI Pharmaceuticals announced that it received a...

23d ago

CASI

CASI Earnings Report this Week: Is It a Buy, Ahead of Earnings?

CASI Pharmaceuticals (CASI) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street analysts...

24d ago

CASI

CASI Pharmaceuticals Advances CID-103 in Promising ITP Study

CASI Pharmaceuticals (($CASI)) announced an update on their ongoing clinical study. CASI Pharmaceuticals is conducting a global Phase...

1M ago

CASI

Casi Pharmaceuticals appoints James Hunag to board of directors

CASI Pharmaceuticals (CASI) announced the appointment of James Huang as an Independent Director to the CASI Board of...

2M ago

CASI

CASI Pharmaceuticals Strengthens Board with Industry Veteran James Huang

CASI Pharmaceuticals ( ($CASI) ) has provided an update. On September 26, 2025, CASI Pharmaceuticals announced the appointment...

2M ago

CASI

CASI announces SMC recommendation to escalate CID-103 dose to next cohort

CASI Pharmaceuticals (CASI) announced that the Safety Monitoring Committee has completed its review of cohort 4 along with...

3M ago

CASI

CASI Pharmaceuticals: Strategic Advancements and Leadership Strengthening Drive Buy Rating with $4.00 Price Target

Sean Lee CFA, an analyst from H.C. Wainwright, maintained the Buy rating on CASI Pharmaceuticals. The associated price...

3M ago

CASI

CASI Pharmaceuticals Strengthens Board with New Appointment

CASI Pharmaceuticals ( ($CASI) ) just unveiled an announcement. On September 2, 2025, CASI Pharmaceuticals announced the appointment...

3M ago

CASI

Casi Pharmaceuticals appoints Barbara Krebs-Pohl to board of directors

CASI Pharmaceuticals (CASI) announced the appointment of Barbara Krebs-Pohl, PhD as an Independent Director to the CASI Board...

3M ago

CASI

CASI Pharmaceuticals Reports Q2 2025 Results and Strategic Asset Divestiture

An announcement from CASI Pharmaceuticals ( ($CASI) ) is now available. On August 29, 2025, CASI Pharmaceuticals announced...

3M ago

CASI

CASI Pharmaceuticals Faces Setback with FOLOTYN® License Expiration in China

The latest announcement is out from CASI Pharmaceuticals ( ($CASI) ). CASI Pharmaceuticals announced that its Import Drug...

3M ago

CASI

CASI FAQ

What was CASI Pharmaceuticals’s price range in the past 12 months?

CASI Pharmaceuticals lowest stock price was $0.93 and its highest was $4.05 in the past 12 months.

What is CASI Pharmaceuticals’s market cap?

CASI Pharmaceuticals’s market cap is $20.61M.

When is CASI Pharmaceuticals’s upcoming earnings report date?

CASI Pharmaceuticals’s upcoming earnings report date is Apr 29, 2026 which is in 146 days.

How were CASI Pharmaceuticals’s earnings last quarter?

CASI Pharmaceuticals released its earnings results on Nov 14, 2025. The company reported -$0.4 earnings per share for the quarter, the consensus estimate of -$0.4 by $0.

Is CASI Pharmaceuticals overvalued?

According to Wall Street analysts CASI Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CASI Pharmaceuticals pay dividends?

CASI Pharmaceuticals does not currently pay dividends.

What is CASI Pharmaceuticals’s EPS estimate?

CASI Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CASI Pharmaceuticals have?

CASI Pharmaceuticals has 15,492,681 shares outstanding.

What happened to CASI Pharmaceuticals’s price movement after its last earnings report?

CASI Pharmaceuticals reported an EPS of -$0.4 in its last earnings report, expectations of -$0.4. Following the earnings report the stock price went down -5.556%.

Which hedge fund is a major shareholder of CASI Pharmaceuticals?

Currently, no hedge funds are holding shares in CASI

Company Description

CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer and other diseases. The company primarily operates in the oncology sector, with a portfolio that includes proprietary and partnered products aimed at addressing unmet medical needs. CASI seeks to leverage its expertise in drug development to bring novel therapies to market, enhancing treatment options for patients worldwide.